García R, Hernández J M, Caballero M D, González M, Galende J, del Cañizo M C, Vázquez L, San Miguel J F
Servicio de Hemàtologia/Departamento Medicina Hospital Universitario, Universidad de Salamanca, Spain.
Br J Cancer. 1993 Dec;68(6):1227-31. doi: 10.1038/bjc.1993.509.
The efficacy of currently available treatments for Hodgkin's disease (HD) has led to a substantial modification in the prognosis of this disease; nevertheless there is still a group of patients that cannot be cured with conventional treatments and who will be candidates for alternative therapy. In the present work we analysed the prognostic influence of the most relevant clinico-biological characteristics of HD in a consecutive series of 137 patients diagnosed and treated in a single institution. Univariate analyses identified six variables with significant prognostic influence, both on achieving complete remission (CR) and overall survival (OS); LDH > 320 U ml-1, age > 45 years, stages IIB, III and IV, extranodal involvement, alkaline phosphatase > 190 UI dl and ESR > 40 mm h. In addition, Hb < 12.5 gr dl-1 and abdominal disease were statistically relevant for CR while a poor performance score (ECOG > or = 2) affected a lower survival. In the multivariate analysis only LDH, age and the clinical stage retained a significant prognostic influence for achieving CR, while the two first factors above, together with performance status were the variables with independent prognostic value with respect to OS. Moreover, only LDH > 320 U ml-1 had prognostic influence in the probability of relapse and disease free survival (DFS), both in the univariate and multivariate analyses. According to the three independent factors obtained in the multivariate analysis for CR (LDH, age and stage) a predictive model was established that allows the stratification of patients into two prognostic groups: one with poor prognosis that includes patients with the three adverse prognostic factors, or two if one of them was elevated LDH, and the other with good prognosis that includes the remaining patients. This model was also able to separate two independent groups of patients with respect to OS and to DFS. In conclusion, the present study shows that LDH is one of the most important prognostic factors in HD.
目前可用的霍奇金淋巴瘤(HD)治疗方法的疗效已使该疾病的预后有了实质性改变;然而,仍有一组患者无法通过传统治疗治愈,他们将成为替代疗法的候选者。在本研究中,我们分析了在单一机构诊断和治疗的连续137例HD患者中最相关的临床生物学特征的预后影响。单因素分析确定了六个对实现完全缓解(CR)和总生存期(OS)有显著预后影响的变量;乳酸脱氢酶(LDH)> 320 U/ml、年龄> 45岁、IIB期、III期和IV期、结外受累、碱性磷酸酶> 190 UI/dl和红细胞沉降率(ESR)> 40 mm/h。此外,血红蛋白(Hb)< 12.5 gr/dl和腹部病变与CR在统计学上相关,而较差的体能状态评分(东部肿瘤协作组(ECOG)≥2)影响较低的生存率。在多因素分析中,只有LDH、年龄和临床分期对实现CR仍有显著的预后影响,而上述前两个因素与体能状态是关于OS具有独立预后价值的变量。此外,在单因素和多因素分析中,只有LDH> 320 U/ml对复发概率和无病生存期(DFS)有预后影响。根据多因素分析中获得的用于CR的三个独立因素(LDH、年龄和分期)建立了一个预测模型,该模型可将患者分为两个预后组:一个预后较差组,包括具有三个不良预后因素的患者,或如果其中一个是LDH升高则为两个不良预后因素的患者,另一个预后良好组,包括其余患者。该模型在OS和DFS方面也能够区分两组独立的患者。总之,本研究表明LDH是HD中最重要的预后因素之一。